Cryoport, Inc. (CYRX) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers Cryoport, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Cryoport is a global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a primary focus on the cell and gene therapy (CGT) market. The company operates through two reportable segments: Life Sciences Services (BioLogistics, BioStorage, BioServices, Cryopreservation) and Life Sciences Products (Cryogenic Systems Manufacturing via MVE Biological Solutions).
A material event during the period was the divestiture of the CRYOPDP specialty courier business to DHL Supply Chain in June 2025 for $133.0 million, classified as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Total Revenue | $176.2 million | $156.8 million |
| Net Income (Loss) | $78.3 million | ($114.8 million) |
| Net Income Attributable to Common Stockholders | $70.3 million | ($122.8 million) |
| Gross Margin | 47.1% | 44.4% |
| Loss from Continuing Operations | ($34.0 million) | ($104.7 million) |
| Income from Discontinued Operations | $112.3 million | ($10.0 million) |
| Cash and Cash Equivalents | $250.5 million | $34.1 million |
| Short-term Investments | $160.7 million | $216.5 million |
| Total Indebtedness (Convertible Notes) | $186.2 million (Principal) | $200.5 million (Principal) |
| Working Capital | $257.2 million | $277.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12.4% to $176.2 million. Life Sciences Services revenue grew 17.6% to $96.5 million, driven by BioLogistics (16.6% growth) and BioStorage/BioServices (22.2% growth). Life Sciences Products revenue grew 6.6% to $79.7 million.
- Profitability Turnaround: The company reported a net income of $78.3 million in 2025, a significant improvement from a net loss of $114.8 million in 2024. This swing was primarily driven by a $117.0 million gain on the divestiture of CRYOPDP and the absence of the $63.8 million goodwill impairment charge recorded in 2024.
- Continuing Operations: Excluding discontinued operations, the company reported a loss from continuing operations of $34.0 million, an improvement from a $104.7 million loss in 2024. Adjusted EBITDA from continuing operations improved from a negative $17.8 million to a negative $5.8 million.
- Debt Reduction: The company repaid the 2025 Convertible Senior Notes ($14.3 million) at maturity and repurchased portions of the 2026 Convertible Senior Notes in prior periods, reducing total principal outstanding to $186.2 million.
- Liquidity: Cash and cash equivalents increased significantly to $250.5 million, bolstered by proceeds from the CRYOPDP divestiture ($210.2 million).
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management highlighted strong demand for CGT supply chain solutions, supporting 760 clinical trials (86 in Phase III) and 20 commercially approved therapies as of year-end. The company is investing in digital capabilities (Cryoportal, AI) and expanding its global footprint, including a new center in Paris (operational Nov 2025) and planned expansion in Santa Ana, CA (late 2026). The divestiture of CRYOPDP is expected to enhance focus on high-value services in EMEA and APAC.
Risks and Contingencies:
- Historical Losses: Despite 2025 profitability, the company has an accumulated deficit of $688.9 million and may incur future losses.
- Debt Obligations: The company has $186.2 million in 2026 Convertible Senior Notes due in December 2026. Failure to generate sufficient cash flow could limit operations.
- Goodwill and Intangibles: The company holds $22.4 million in goodwill and $138.1 million in intangible assets. Future impairments could materially impact results.
- Geopolitical and Trade Risks: Exposure to foreign currency fluctuations, tariffs, and trade restrictions (e.g., U.S.-China relations) could adversely affect operations.
- Cybersecurity: Reliance on critical information systems (Cryoportal) exposes the company to cyberattack risks that could disrupt operations.
Key Facts for Investor Verification
- Divestiture Impact: Verify the sustainability of profitability without the one-time $117.0 million gain from the CRYOPDP sale. The core business (continuing operations) remains loss-making on a GAAP basis.
- Debt Maturity Wall: Confirm the company's ability to refinance or repay the $186.2 million 2026 Convertible Senior Notes maturing in December 2026.
- CGT Market Dependence: Assess the concentration risk in the cell and gene therapy market, which is the company's primary growth driver but subject to regulatory and clinical trial volatility.
- Intangible Asset Valuation: Review the assumptions used in the goodwill and indefinite-lived intangible asset impairment tests, particularly for the MVE reporting unit, given the history of impairments in 2023 and 2024.
- Stock Repurchase Program: Note the remaining $63.9 million authorization under the 2024 Repurchase Program and the potential for further dilution from convertible notes and preferred stock.